Nephrology - Global Cardiology Academy

1-16 of 54

Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
CME/CE
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
- Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
CME/CE
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Brendon Neuen, MBBS, PhD; Katherine Tuttle, MD
0.25 credits
- Brendon Neuen, MBBS, PhD
- Katherine Tuttle, MD
0.25 credits
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart Matters
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD; Payal Kohli, MD, FACC
- Shelina Ramnarine, PhD
- Payal Kohli, MD, FACC
Understanding Residual Cardiovascular Risk in CKD and T2D
Understanding Residual Cardiovascular Risk in CKD and T2D
Diabetes Discourse
Understanding Residual Cardiovascular Risk in CKD and T2D
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
Finerenone Subgroup Analyses in Patients With Glomerulonephritis
Finerenone Subgroup Analyses in Patients With Glomerulonephritis
Nephrology
Finerenone Subgroup Analyses in Patients With Glomerulonephritis
Brendon Neuen, MBBS, PhD
- Brendon Neuen, MBBS, PhD
Efficacy and Safety of Finerenone in Patients With Non-Diabetic CKD: Insight From FIND-CKD
Efficacy and Safety of Finerenone in Patients With Non-Diabetic CKD: Insight From FIND-CKD
Nephrology
Efficacy and Safety of Finerenone in Patients With Non-Diabetic CKD: Insight From FIND-CKD
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
Nephrology
Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart Matters
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP; Anu Lala, MD
- Brian P. McDonough, MD, FAAFP
- Anu Lala, MD
- Martha Gulati, MD, MS, FACC, FAHA
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CE
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD; Julio Núñez, MD, PhD
0.25 credits
- Patrick Rossignol, MD, PhD
- Julio Núñez, MD, PhD
0.25 credits
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Heart Matters
Hypertension Across Diverse Populations: Practical Strategies for Equitable Care
Alexandria May, PharmD, BCPS; Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
- Alexandria May, PharmD, BCPS
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Connecting Chronic Kidney Disease and Cardiovascular Risk in Primary Care
Connecting Chronic Kidney Disease and Cardiovascular Risk in Primary Care
Heart Matters
Connecting Chronic Kidney Disease and Cardiovascular Risk in Primary Care
Alexandria May, PharmD, BCPS; Javed Butler, MD, MPH, MBA
- Alexandria May, PharmD, BCPS
- Javed Butler, MD, MPH, MBA
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Heart Matters
Steroidal vs Nonsteroidal MRAs: Implications for Heart Failure Care
Steve Jackson, PharmD; Robert J. Mentz, MD, FHFSA, FACC
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
Making UACR a Routine Part of Diabetes Care
Making UACR a Routine Part of Diabetes Care
Heart Matters
Making UACR a Routine Part of Diabetes Care
Steve Jackson, PharmD; Robert J. Mentz, MD, FHFSA, FACC
- Steve Jackson, PharmD
- Robert J. Mentz, MD, FHFSA, FACC
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Scott Solomon, MD
0.25 credits
- Scott Solomon, MD
0.25 credits
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
- prof. Hiddo Heerspink

Prev
1
2
3
4
Next

1/4